25 September 2025

Economic evaluation of HMG-CoA reductase inhibitors (statin) for primary prevention of cardiovascular diseases among Thai population (in Thai language)

View Count

Share this research

Project Code 01-308-2550

Country

Thailand

Project Duration

Start : 1 January 2007

Research Status

Completed 100%

Complete Research Report

Quantity 0 files

Download Count

0 times

All research

25 September 2025

Economic evaluation of HMG-CoA reductase inhibitors (statin) for primary prevention of cardiovascular diseases among Thai population (in Thai language)

About Project

Content

The aims of this study were 1) to estimate the incremental cost-effectiveness ratio (ICER) of offering statins for primary prevention of CVD for each CVD risk group, and 2) to estimate the budget impact if the statins were prescribed to those people living with different CVD risks. This was a model-based economic evaluation. A Markov model was constructed to estimate the costs and benefits in terms of quality adjusted life year (QALY) gained by providing statins in comparison to a “null” or “do nothing” scenario. The study revealed that if a ceiling threshold is equal to 3 times that of Gross Domestic Product per capita or 300,000 Baht per QALY, a generic simvastatin is a cost-effective intervention for all people except those with less than 2.5% CV D risk. However, if the ceiling threshold is equal to 100,000 Baht per QAL Y, a generic simvastatin is still considered as a cost-effective intervention if it is offered to Thai people with > 30% CVD risk.

Research Type

Others

Related Technologies

Pharmaceuticals

Others

Funding Source

Strategy and Planning Division, Office of Permanent Secretary, Ministry of Public Health, Thailand